[177Lu]Lu-FL801 / Full-Life Technologies Limited - LARVOL DELTA

Discovery of FL801, a B7-H3-targeting nanobody-based radioligand vector, using Clear-XTM linker technology (AACR 2025) - "In summary, the preclinical data package collectively supports to proceed towards clinical studies of [177Lu]Lu-FL801 as a potential therapeutic option for B7-H3 positive tumors. In addition, this work validated the effectiveness of Clear-X™ linker technology in optimizing VHH-RDCs, and we expect Clear-X™ is also applicable to other protein-based RDCs with similar molecular sizes."

Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • CD276 • PD-L1